DDOST-CDG (CDG-Ir)
DDOST-CDG (CDG-Ir)
DDOST-CDG (CDG-Ir), also known as Congenital Disorder of Glycosylation type Ir, is a rare genetic disorder that affects the process of glycosylation, which is the attachment of sugars to proteins and lipids. This process is crucial for the proper function of many proteins and lipids in the body. DDOST-CDG is part of a larger group of disorders known as Congenital Disorders of Glycosylation (CDG).
Genetics
DDOST-CDG is caused by mutations in the DDOST gene, which encodes the enzyme dolichyl-diphosphooligosaccharide—protein glycosyltransferase subunit 1. This enzyme is essential for the initial steps of N-linked glycosylation, a type of glycosylation that occurs in the endoplasmic reticulum. Mutations in the DDOST gene lead to defective glycosylation, resulting in a wide range of clinical symptoms.
Clinical Features
The clinical presentation of DDOST-CDG can vary widely among affected individuals. Common symptoms include:
- Developmental delay
- Intellectual disability
- Hypotonia
- Seizures
- Coagulopathy
- Liver dysfunction
- Failure to thrive
Diagnosis
Diagnosis of DDOST-CDG typically involves a combination of clinical evaluation, biochemical testing, and genetic testing. Biochemical tests may show abnormal glycosylation patterns in serum glycoproteins. Genetic testing can confirm the diagnosis by identifying mutations in the DDOST gene.
Treatment
There is currently no cure for DDOST-CDG. Treatment is primarily supportive and symptomatic, focusing on managing the various symptoms and complications associated with the disorder. This may include physical therapy, occupational therapy, and medications to control seizures and other symptoms.
Prognosis
The prognosis for individuals with DDOST-CDG varies depending on the severity of the symptoms and the specific mutations involved. Early diagnosis and supportive care can improve the quality of life for affected individuals.
Related Pages
- Congenital Disorders of Glycosylation
- Glycosylation
- Genetic disorder
- Endoplasmic reticulum
- Developmental delay
- Intellectual disability
- Hypotonia
- Seizures
- Coagulopathy
- Liver dysfunction
- Failure to thrive
Template:CongenitalDisorder-stub
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
